[go: up one dir, main page]

WO2005047261A1 - Non-hygroscopic crystalline form of gatifloxacin - Google Patents

Non-hygroscopic crystalline form of gatifloxacin Download PDF

Info

Publication number
WO2005047261A1
WO2005047261A1 PCT/IB2004/003600 IB2004003600W WO2005047261A1 WO 2005047261 A1 WO2005047261 A1 WO 2005047261A1 IB 2004003600 W IB2004003600 W IB 2004003600W WO 2005047261 A1 WO2005047261 A1 WO 2005047261A1
Authority
WO
WIPO (PCT)
Prior art keywords
gatifloxacin
methanol
crystalline form
room temperature
crude
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/003600
Other languages
French (fr)
Inventor
Antonio Cosme Gomez
Javier Villasante Prieto
Francisco Eugenio Palomo Nicolau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimica Sintetica SA
Original Assignee
Quimica Sintetica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica SA filed Critical Quimica Sintetica SA
Publication of WO2005047261A1 publication Critical patent/WO2005047261A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to a new non-hygroscopic crystalline form of the active pharmaceutical substance gatifloxacin.
  • Gatifloxacin is the international common name of l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7- (3-methyl-l- piperazinyl) -4-oxo-3-quinolinecarboxylic acid of formula (I), which finds application in medicine and is known for its antibiotic activity:
  • European patent application EP-A-230295 discloses the preparation of gatifloxacin, which is isolated in hemihydrate form (1/2 H 2 0) , corresponding to 2.34% in calculated weight of water.
  • European patent application EP-A-805156 discloses a sesquihydrated crystalline form (3/2 H 2 O) of gatifloxacin, corresponding to 6.72% in calculated weight of water. Both crystalline forms have a tendency to absorb water and to give rise to other forms with a higher content in hydration water.
  • Patent application WO-A-0222126 discloses gatifloxacin pentahydrate (5 H 2 0) , corresponding to 19.3% in calculated weight of water.
  • the object of the present invention is a new non- hygroscopic crystalline form of gatifloxacin named form II gatifloxacin. Also object of this invention is a process for preparing form II gatifloxacin. Also forming part of this invention is the use of form II gatifloxacin for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
  • Figure 1 shows the powder X-ray diffractogram of form II gatifloxacin.
  • Figure 2 shows the powder X-ray diffractogram of gatifloxacin pentahydrate .
  • Figure 3 shows the powder X-ray diffractogram of gatifloxacin sesquihydrate.
  • Figure 4 shows the powder X-ray diffractogram of gatifloxacin hemihydrate, taken from North American patent US5880283. Said patent includes only the X-ray diffractogram, without the corresponding list of peaks at the different 2 ⁇ angles.
  • Figure 5 shows the infrared spectrum recorded on
  • Figure 6 shows the infrared spectrum recorded on KBr tablet of gatifloxacin pentahydrate.
  • Figure 7 shows the infrared spectrum recorded on KBr tablet of gatifloxacin sesquihydrate.
  • Figure 8 shows the infrared spectrum recorded on KBr tablet of gatifloxacin hemihydrate, taken from North American patent US5880283.
  • Figure 9 shows the 13 C nuclear magnetic resonance spectrum of the new non-hygroscopic crystalline form of gatifloxacin.
  • non-hygroscopic crystalline form of gatifloxacin which have been named form II by the authors of this invention and which contains between 8 and 9% by weight of water.
  • the new non-hygroscopic crystalline form of gatifloxacin is characterised by a powder X-ray diffractogram which is different from the powder X-ray diffractograms of the other known forms of gatifloxacin, as can be seen from Figures 1, 2, 3 and 4.
  • the powder X-ray diffractogram of gatifloxacin pentahydrate ( Figure 2) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126.
  • the powder diffractogram of gatifloxacin sesquihydrate ( Figure 3) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin sesquihydrate found in Example 1 of patent application EP-A-805156.
  • the X-ray diffractogram of the hemihydrate form ( Figure 4) is that disclosed in the specification of North
  • the new non-hygroscopic crystalline form of gatifloxacin, object of the invention has a powder X - ray diffractogram that shows peaks with a relative intensity higher than 5%, at the following 2 ⁇ angles:
  • a PHILIPS X'Pert model automatic diffractometer equipped with a Cu tube and a graphite secondary monochromator was used, with the following technical specifications : - K ⁇ Cu wavelength: 1.5419 A; - receiving slit: 0.1 mm; Soller: 0.04 radians; dispersion slit and divergence slit: 1°
  • the tube works at 40 kV and 50 mA. Sweeping was carried out continuously at the 2 ⁇ interval between 5 and 40° with 0.03° pass and 1-second pass time.
  • the new non-hygroscopic crystalline form of gatifloxacin is also characterised by its infrared spectrum recorded on potassium bromide tablet, which is different from the spectrums of the other known forms of gatifloxacin, as shown by Figures 5, 6, 7 and 8.
  • the infrared spectrum of gatifloxacin pentahydrate ( Figure 6) has been recorded on potassium bromide tablet on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126.
  • the non-hygroscopic crystalline form of gatifloxacin object of the invention can be obtained by means of a process that includes the following steps : the crude gatifloxacin is dissolved in methanol by heating to reflux temperature, it is cooled slowly to room temperature under stirring, and - it is kept at rest at room temperature for a period of time between 8 and 14 hours.
  • the initial crude gatifloxacin can be prepared according to the process described in Example 3 of European patent application EP-A-230295.
  • the solution of crude gatifloxacin in methanol at reflux is preferably prepared by using between 50 and 55 volumes of methanol for each unit by weight of crude gatifloxacin.
  • the solution is cooled slowly from the reflux temperature of the methanol down to room temperature. This slow cooling, which is necessary for obtaining the crystalline form of gatifloxacin object of the invention, is preferably carried out for approximately five hours . Crystallisation of the product begins over this period of time.
  • the suspension containing the solid is kept at rest (without stirring) at room temperature for a period of time between 8 and 14 hours . This period of time is necessary for obtaining the crystalline form object of the invention.
  • the form II gatifloxacin can be used for seeding in the cooling stage from the reflux temperature of the methanol down to room temperature, thereby facilitating the formation of crystals .
  • the seeding process is carried out every 2° C from a temperature of 60° C until the seeding amount is inconsiderable when compared with the amount of product crystallised.
  • the method for obtaining the new non-hygroscopic form of gatifloxacin can be completed with the following steps: - the suspension is cooled with stirring to a temperature between 0° C and 5° C, the solid product is filtered, and the product is dried in an oven in vacuo.
  • the cooling of the suspension at a temperature ranging between 0° C and 5° C is carried out by refrigeration with cold water and with stirring, and said temperature is maintained for at least 1 hour.
  • the solid is filtered and washed with cold methanol .
  • the moist solid is dried at 40° C in vacuo for 6 hours and, once cold, is left in contact with the atmosphere at room temperature until it reaches a water content by weight between 8 and 9%.
  • the new non-hygroscopic crystalline form of gatifloxacin obtained according to this process remains stable in its water content for at least 3 months, even at room temperature and in contact with the atmosphere.
  • the new crystalline form of gatifloxacin is characterised by its powder X-ray diffractogram, infrared spectroscopy on potassium bromide tablet, 13 C nuclear magnetic resonance and water analysis using the Karl- Fischer method.
  • the new crystalline form of gatifloxacin which contains between 8 and 9% in weight of water is not hygroscopic, as its water content remains stable for at least 3 months, even at room temperature and in contact with the atmosphere, and it has excellent properties of disintegration and dissolution rate, which make it very well-suited for use as an active substance in the preparation of pharmaceutical formulations, preferably for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
  • the example that follows below is disclosed for the purpose of providing a detailed explanation of a specific embodiment of the process of preparation to those skilled in the art in order to yield the compound of the invention.
  • Example 1 Preparing form II gatifloxacin 35.9 g of crude gatifloxacin with a water content of 2.74% by weight is dissolved in 1805 mL of methanol (approximately 50 mL of methanol per gram of crude gatifloxacin) at reflux temperature. The solution obtained is left to cool slowly for approximately 5 hours under stirring. During this period, precipitation of the product starts. The resulting suspension is kept for a further 12 hours at room temperature and without stirring. Subsequently, stirring is recommenced, it is cooled to a temperature between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel .
  • the product retained in the filter is washed with 35 mL of cold methanol and dried in an oven In vacuo at 40° C for approximately 6 hours .
  • the product is then left to dry in a desiccator In vacuo for 45 minutes and the vacuum is broken with nitrogen. 32.9 g of a white solid is obtained, having a water content when it is taken out of the desiccator of 3.45% by weight.
  • the product is kept at room temperature and in contact with the atmosphere, and after three days has a water content of 8.35% by weight, which remains stable for at least 3 months under those conditions.
  • Example 2 Preparing form II gatifloxacin with seeding of crystals 10 g of crude gatifloxacin with a water content of 3.70% by weight are added to 500 mL methanol (solvent to solute ratio: 50 mL of methanol per gram of crude gatifloxacin) and heated to reflux temperature. Once the reflux temperature has been reached, a further 20 mL of methanol are added in order to achieve total dissolution of the product (solvent to solute ratio: 52 mL of methanol per gram of crude gatifloxacin) . The solution obtained is left to cool slowly for approximately 5 hours under stirring.
  • seeding with crystals of form II gatifloxacin is carried out every 2° C from a temperature of 60° C.
  • the resulting suspension is kept for a further 12 hours at rest at room temperature.
  • stirring is recommenced, it is cooled to a temperature ranging between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel.
  • the product retained in the filter is washed with cold methanol (2 x 10 mL) and dried in an oven in vacuo at 40° C for approximately 6 hours.
  • the product is then left to cool in a desiccator in vacuo for 45 minutes and the vacuum is broken with nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a non-hygroscopic crystalline form of gatifloxacin that contains a weight of water ranging between 8 and 9%, to a process for preparing it and to its use as an active ingredient in the preparation of pharmaceutical formulations.

Description

NON-HYGROSCOPIC CRYSTALLINE FORM OF GATIFLOXACIN
Field of the technique This invention relates to a new non-hygroscopic crystalline form of the active pharmaceutical substance gatifloxacin.
Prior state of the art Gatifloxacin is the international common name of l-cyclopropyl-6-fluoro-l,4-dihydro-8-methoxy-7- (3-methyl-l- piperazinyl) -4-oxo-3-quinolinecarboxylic acid of formula (I), which finds application in medicine and is known for its antibiotic activity:
Figure imgf000002_0001
European patent application EP-A-230295 discloses the preparation of gatifloxacin, which is isolated in hemihydrate form (1/2 H20) , corresponding to 2.34% in calculated weight of water. European patent application EP-A-805156 discloses a sesquihydrated crystalline form (3/2 H2O) of gatifloxacin, corresponding to 6.72% in calculated weight of water. Both crystalline forms have a tendency to absorb water and to give rise to other forms with a higher content in hydration water. Patent application WO-A-0222126 discloses gatifloxacin pentahydrate (5 H20) , corresponding to 19.3% in calculated weight of water. There therefore exists a need to have another hydrated crystalline form of gatifloxacin which is not hygroscopic and has a lower water content. The authors of the present invention have discovered a new non-hygroscopic crystalline form of gatifloxacin, which have been designated form II by the authors of this invention and which contains a weight of water ranging between 8 and 9%.
Object of the invention The object of the present invention is a new non- hygroscopic crystalline form of gatifloxacin named form II gatifloxacin. Also object of this invention is a process for preparing form II gatifloxacin. Also forming part of this invention is the use of form II gatifloxacin for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
Brief description of the drawings Figure 1 shows the powder X-ray diffractogram of form II gatifloxacin. Figure 2 shows the powder X-ray diffractogram of gatifloxacin pentahydrate . Figure 3 shows the powder X-ray diffractogram of gatifloxacin sesquihydrate. Figure 4 shows the powder X-ray diffractogram of gatifloxacin hemihydrate, taken from North American patent US5880283. Said patent includes only the X-ray diffractogram, without the corresponding list of peaks at the different 2Θ angles. Figure 5 shows the infrared spectrum recorded on
KBr tablet of form II gatifloxacin. Figure 6 shows the infrared spectrum recorded on KBr tablet of gatifloxacin pentahydrate. Figure 7 shows the infrared spectrum recorded on KBr tablet of gatifloxacin sesquihydrate. Figure 8 shows the infrared spectrum recorded on KBr tablet of gatifloxacin hemihydrate, taken from North American patent US5880283. Figure 9 shows the 13C nuclear magnetic resonance spectrum of the new non-hygroscopic crystalline form of gatifloxacin.
Detailed description of the invention The authors of the present invention have discovered a non-hygroscopic crystalline form of gatifloxacin, which have been named form II by the authors of this invention and which contains between 8 and 9% by weight of water. The new non-hygroscopic crystalline form of gatifloxacin is characterised by a powder X-ray diffractogram which is different from the powder X-ray diffractograms of the other known forms of gatifloxacin, as can be seen from Figures 1, 2, 3 and 4. The powder X-ray diffractogram of gatifloxacin pentahydrate (Figure 2) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126. The powder diffractogram of gatifloxacin sesquihydrate (Figure 3) was recorded on the basis of the product prepared according to the method of preparation of gatifloxacin sesquihydrate found in Example 1 of patent application EP-A-805156. The X-ray diffractogram of the hemihydrate form (Figure 4) is that disclosed in the specification of North
American patent US5880283, wherein the diffractogram of the hemihydrate (comparative substance) is compared with that of the sesquihydrate. The new non-hygroscopic crystalline form of gatifloxacin, object of the invention, has a powder X - ray diffractogram that shows peaks with a relative intensity higher than 5%, at the following 2Θ angles:
Figure imgf000005_0001
For recording the X-ray diffractograms, a PHILIPS X'Pert model automatic diffractometer equipped with a Cu tube and a graphite secondary monochromator was used, with the following technical specifications : - Kα Cu wavelength: 1.5419 A; - receiving slit: 0.1 mm; Soller: 0.04 radians; dispersion slit and divergence slit: 1° The tube works at 40 kV and 50 mA. Sweeping was carried out continuously at the 2Θ interval between 5 and 40° with 0.03° pass and 1-second pass time. The new non-hygroscopic crystalline form of gatifloxacin is also characterised by its infrared spectrum recorded on potassium bromide tablet, which is different from the spectrums of the other known forms of gatifloxacin, as shown by Figures 5, 6, 7 and 8. The infrared spectrum of gatifloxacin pentahydrate (Figure 6) has been recorded on potassium bromide tablet on the basis of the product prepared according to the method of preparation of gatifloxacin pentahydrate described in Example 1 of patent application WO-A-0222126. The infrared spectrum of gatifloxacin sesquihydrate (Figure 7) has been recorded on potassium bromide tablet on the basis of the product prepared according to the method of preparation of gatifloxacin sesquihydrate to be found in Example 1 of patent application EP-A-805156. The infrared spectrum of gatifloxacin hemihydrate (Figure 8) is that shown in the specification of North
American patent US5880283, wherein the infrared spectrum of the hemihydrate (comparative substance) is compared with that of the sesquihydrate. The 13C nuclear magnetic resonance spectrum (Figure 9) has been recorded on a solid sample of the substance object of the invention. The non-hygroscopic crystalline form of gatifloxacin object of the invention can be obtained by means of a process that includes the following steps : the crude gatifloxacin is dissolved in methanol by heating to reflux temperature, it is cooled slowly to room temperature under stirring, and - it is kept at rest at room temperature for a period of time between 8 and 14 hours. The initial crude gatifloxacin can be prepared according to the process described in Example 3 of European patent application EP-A-230295. The solution of crude gatifloxacin in methanol at reflux is preferably prepared by using between 50 and 55 volumes of methanol for each unit by weight of crude gatifloxacin. Once the crude gatifloxacin has been dissolved at the reflux temperature of methanol, the solution is cooled slowly from the reflux temperature of the methanol down to room temperature. This slow cooling, which is necessary for obtaining the crystalline form of gatifloxacin object of the invention, is preferably carried out for approximately five hours . Crystallisation of the product begins over this period of time. The suspension containing the solid is kept at rest (without stirring) at room temperature for a period of time between 8 and 14 hours . This period of time is necessary for obtaining the crystalline form object of the invention. Eventually, once the form II gatifloxacin has been already formed and isolated, it can be used for seeding in the cooling stage from the reflux temperature of the methanol down to room temperature, thereby facilitating the formation of crystals . The seeding process is carried out every 2° C from a temperature of 60° C until the seeding amount is inconsiderable when compared with the amount of product crystallised. The method for obtaining the new non-hygroscopic form of gatifloxacin can be completed with the following steps: - the suspension is cooled with stirring to a temperature between 0° C and 5° C, the solid product is filtered, and the product is dried in an oven in vacuo. The cooling of the suspension at a temperature ranging between 0° C and 5° C is carried out by refrigeration with cold water and with stirring, and said temperature is maintained for at least 1 hour. The solid is filtered and washed with cold methanol . The moist solid is dried at 40° C in vacuo for 6 hours and, once cold, is left in contact with the atmosphere at room temperature until it reaches a water content by weight between 8 and 9%. The new non-hygroscopic crystalline form of gatifloxacin obtained according to this process remains stable in its water content for at least 3 months, even at room temperature and in contact with the atmosphere. The new crystalline form of gatifloxacin is characterised by its powder X-ray diffractogram, infrared spectroscopy on potassium bromide tablet, 13C nuclear magnetic resonance and water analysis using the Karl- Fischer method. Surprisingly, it was found that the new crystalline form of gatifloxacin which contains between 8 and 9% in weight of water is not hygroscopic, as its water content remains stable for at least 3 months, even at room temperature and in contact with the atmosphere, and it has excellent properties of disintegration and dissolution rate, which make it very well-suited for use as an active substance in the preparation of pharmaceutical formulations, preferably for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin. The example that follows below is disclosed for the purpose of providing a detailed explanation of a specific embodiment of the process of preparation to those skilled in the art in order to yield the compound of the invention.
Example 1. - Preparing form II gatifloxacin 35.9 g of crude gatifloxacin with a water content of 2.74% by weight is dissolved in 1805 mL of methanol (approximately 50 mL of methanol per gram of crude gatifloxacin) at reflux temperature. The solution obtained is left to cool slowly for approximately 5 hours under stirring. During this period, precipitation of the product starts. The resulting suspension is kept for a further 12 hours at room temperature and without stirring. Subsequently, stirring is recommenced, it is cooled to a temperature between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel . The product retained in the filter is washed with 35 mL of cold methanol and dried in an oven In vacuo at 40° C for approximately 6 hours . The product is then left to dry in a desiccator In vacuo for 45 minutes and the vacuum is broken with nitrogen. 32.9 g of a white solid is obtained, having a water content when it is taken out of the desiccator of 3.45% by weight. The product is kept at room temperature and in contact with the atmosphere, and after three days has a water content of 8.35% by weight, which remains stable for at least 3 months under those conditions.
Example 2.- Preparing form II gatifloxacin with seeding of crystals 10 g of crude gatifloxacin with a water content of 3.70% by weight are added to 500 mL methanol (solvent to solute ratio: 50 mL of methanol per gram of crude gatifloxacin) and heated to reflux temperature. Once the reflux temperature has been reached, a further 20 mL of methanol are added in order to achieve total dissolution of the product (solvent to solute ratio: 52 mL of methanol per gram of crude gatifloxacin) . The solution obtained is left to cool slowly for approximately 5 hours under stirring. During this period seeding with crystals of form II gatifloxacin, obtained according to Example 1, is carried out every 2° C from a temperature of 60° C. The resulting suspension is kept for a further 12 hours at rest at room temperature. Subsequently, stirring is recommenced, it is cooled to a temperature ranging between 0 and 5° C over a water/ice bath for approximately 1 hour and filtered through a Buchner funnel. The product retained in the filter is washed with cold methanol (2 x 10 mL) and dried in an oven in vacuo at 40° C for approximately 6 hours. The product is then left to cool in a desiccator in vacuo for 45 minutes and the vacuum is broken with nitrogen. 9.45 g of a white solid is obtained, having a water content at the time of taking it out of the desiccator of 3.38% by weight. In contact with the atmosphere and at room temperature, the product reaches a water content of between 8 and 9% by weight and remains stable for at least 3 months under such conditions.

Claims

1. A non-hygroscopic crystalline form of gatifloxacin, characterised in that its powder X-ray diffractogram shows peaks with a relative intensity higher than 5%, at the following 2Θ angles,
Figure imgf000011_0001
and in that it contains between 8 and 9% by weight of water.
2. A process for preparing a crystalline form of gatifloxacin, characterised in that it includes the following steps: the crude gatifloxacin is dissolved in methanol by heating to reflux temperature, it is cooled slowly to room temperature under stirring, and it is kept at rest at room temperature for a period of time ranging between 8 and 14 hours.
3. A process according to Claim 2, characterised in that the crude gatifloxacin is dissolved in methanol using between 50 and 55 volumes of methanol for each unit by weight of crude gatifloxacin.
4. A process according to Claims 2 and 3, characterised in that the slow cooling is carried out for five hours.
5. A process according to Claims 2 to 4, characterised in that seeding with crystals of form II gatifloxacin is carried out in the slow cooling step from the reflux temperature of the methanol down to room temperature .
6. A process according to Claims 2 to 5, characterised in that it also includes the following steps: - the suspension is cooled with stirring to a temperature between 0° C and 5° C, - the solid product is filtered, and the product is dried in an oven in vacuo.
7. Use of the form of gatifloxacin according to Claim 1 for the manufacture of a medicament for the treatment of infectious diseases of bacterial origin.
PCT/IB2004/003600 2003-11-13 2004-11-05 Non-hygroscopic crystalline form of gatifloxacin Ceased WO2005047261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP-200302642 2003-11-13
ES200302642A ES2232310B1 (en) 2003-11-13 2003-11-13 GATIFLOXACINO NON-HYGROSCOPIC CRYSTALLINE FORMULA.

Publications (1)

Publication Number Publication Date
WO2005047261A1 true WO2005047261A1 (en) 2005-05-26

Family

ID=34586126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003600 Ceased WO2005047261A1 (en) 2003-11-13 2004-11-05 Non-hygroscopic crystalline form of gatifloxacin

Country Status (2)

Country Link
ES (1) ES2232310B1 (en)
WO (1) WO2005047261A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805156A1 (en) * 1994-12-21 1997-11-05 Kyorin Pharmaceutical Co., Ltd. 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
WO2002022126A1 (en) * 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
WO2003086402A1 (en) * 2002-04-08 2003-10-23 Dr. Reddy's Laboratories Limited ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)
WO2003094919A2 (en) * 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
WO2004087688A1 (en) * 2003-04-02 2004-10-14 Hetero Drugs Limited Novel crystalline forms of gatifloxacin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805156A1 (en) * 1994-12-21 1997-11-05 Kyorin Pharmaceutical Co., Ltd. 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
WO2002022126A1 (en) * 2000-09-13 2002-03-21 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
WO2003086402A1 (en) * 2002-04-08 2003-10-23 Dr. Reddy's Laboratories Limited ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)
WO2003094919A2 (en) * 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
WO2004087688A1 (en) * 2003-04-02 2004-10-14 Hetero Drugs Limited Novel crystalline forms of gatifloxacin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITAIN ET AL: "Polymorphism in Pharmaceutical Solids passage", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, XX, XX, 1999, pages 235 - 238, XP002278123 *
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *

Also Published As

Publication number Publication date
ES2232310B1 (en) 2006-08-01
ES2232310A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
JP5774732B2 (en) Method for the synthesis of moxifloxacin hydrochloride
EP1615645B1 (en) A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for the preparation thereof
TWI519532B (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
KR20160003899A (en) Macrolide solid-state forms
WO1992017473A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
CN104640864A (en) Ticagrelor adducts with divalent metal salts
JP2015508090A (en) Solid form dabigatran etexilate mesylate and process for its preparation
KR20040104677A (en) Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
KR20010040711A (en) Salts of Paroxetine
WO2005047261A1 (en) Non-hygroscopic crystalline form of gatifloxacin
CA2131761C (en) Crystals of pyridonecarboxylic acid derivative
WO2003031391A1 (en) New anhydrous crystalline forms of gabapentin
HUP0103651A2 (en) Paroxetine maleate and process for its preparation
JP5698226B2 (en) Crystalline phase of 2 '-{[2- (4-methoxy-phenyl) -acetylamino] -methyl} -biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl) -amide
US20070032505A1 (en) Crystalline form of gatifloxacin
US20040053967A1 (en) 3-(3-Amidinophenyl)-5-[({[1-(1-(iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
JP2002538158A (en) 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo- Crystal modification C of 3-quinolinecarboxylic acid
JP4732361B2 (en) 1-cyclopropyl-7-((S, S) -2,8-diazadicyclo (4.3.0) non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4-hydrochloride Polymorphs of oxo-3-quinolinecarboxylic acid and process for the preparation thereof
WO2000008016A1 (en) Paroxetine salts
CA2576307A1 (en) Crystalline forms of 1,24(s)-dihydroxy vitamin d2
WO2022081502A1 (en) Solid state forms of lorecivivint
KR20070030962A (en) Process for preparing novel ondansetron crystal forms
WO2009135577A1 (en) Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2- (4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
CZ20002845A3 (en) Paroxetine salts
AU2002330220A1 (en) New anhydrous crystalline forms of gabapentin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURUANT TO RULE 69(1) EPC, FORM 1205A DATED 23.10.2006

122 Ep: pct application non-entry in european phase